Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

MNPR

Monopar Therapeutics (MNPR)

Monopar Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:MNPR
DateTimeSourceHeadlineSymbolCompany
05/31/20244:56PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MNPRMonopar Therapeutics Inc
05/30/20246:10PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MNPRMonopar Therapeutics Inc
05/24/20244:59PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MNPRMonopar Therapeutics Inc
05/24/20248:00AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:MNPRMonopar Therapeutics Inc
05/24/20248:00AMGlobeNewswire Inc.Monopar Announces CFO SuccessionNASDAQ:MNPRMonopar Therapeutics Inc
05/09/20247:00AMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:MNPRMonopar Therapeutics Inc
05/09/20247:00AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:MNPRMonopar Therapeutics Inc
05/09/20247:00AMGlobeNewswire Inc.Monopar Therapeutics Reports First Quarter 2024 Financial Results and Strategic Focus on its Radiopharma PipelineNASDAQ:MNPRMonopar Therapeutics Inc
04/18/20248:00AMGlobeNewswire Inc.Monopar Announces Radiopharma Presentation Selected for Society of Nuclear Medicine and Molecular Imaging 2024 Annual MeetingNASDAQ:MNPRMonopar Therapeutics Inc
04/16/20248:00AMGlobeNewswire Inc.Monopar Announces Filing of Patent Protecting MNPR-101 Radiopharma Optimization FindingsNASDAQ:MNPRMonopar Therapeutics Inc
04/10/20248:00AMGlobeNewswire Inc.Monopar Initiates Radiopharma Phase 1 Clinical Trial for MNPR-101-Zr in Advanced Cancer PatientsNASDAQ:MNPRMonopar Therapeutics Inc
03/28/20247:00AMGlobeNewswire Inc.Monopar Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent DevelopmentsNASDAQ:MNPRMonopar Therapeutics Inc
03/07/20248:30AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:MNPRMonopar Therapeutics Inc
03/05/20247:00AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:MNPRMonopar Therapeutics Inc
03/05/20247:00AMGlobeNewswire Inc.Monopar Announces Positive Preclinical Therapeutic Isotope Data for its MNPR-101 Radiopharma ProgramNASDAQ:MNPRMonopar Therapeutics Inc
02/28/20241:45PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:MNPRMonopar Therapeutics Inc
02/27/20247:00AMGlobeNewswire Inc.Monopar Provides Update on MNPR-101-Zr Radiopharma Clinical TrialNASDAQ:MNPRMonopar Therapeutics Inc
02/27/20246:59AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:MNPRMonopar Therapeutics Inc
02/22/20247:00AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:MNPRMonopar Therapeutics Inc
02/22/20247:00AMGlobeNewswire Inc.Monopar Announces Promising Preclinical Data for its MNPR-101 Radiopharma Program Targeting Advanced CancersNASDAQ:MNPRMonopar Therapeutics Inc
02/20/20248:00AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:MNPRMonopar Therapeutics Inc
02/20/20248:00AMGlobeNewswire Inc.Monopar Receives Clearance to Proceed with First-in-Human Phase 1 Trial of Novel Radiopharmaceutical MNPR-101-Zr in Advanced CancersNASDAQ:MNPRMonopar Therapeutics Inc
01/03/20247:39PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MNPRMonopar Therapeutics Inc
01/03/20247:36PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MNPRMonopar Therapeutics Inc
11/09/20237:01AMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:MNPRMonopar Therapeutics Inc
11/09/20237:00AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:MNPRMonopar Therapeutics Inc
11/09/20237:00AMGlobeNewswire Inc.Monopar Therapeutics Reports Third Quarter 2023 Financial Results and Recent DevelopmentsNASDAQ:MNPRMonopar Therapeutics Inc
11/01/20237:00AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:MNPRMonopar Therapeutics Inc
11/01/20237:00AMGlobeNewswire Inc.Monopar Presents Data Showing Tumor Reduction Benefit of Camsirubicin from Ongoing Phase 1b at the 2023 Connective Tissue Oncology Society (CTOS) Annual MeetingNASDAQ:MNPRMonopar Therapeutics Inc
10/10/20237:00AMGlobeNewswire Inc.Monopar to Participate in the Roth MKM 2023 Healthcare Opportunities ConferenceNASDAQ:MNPRMonopar Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:MNPR